Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/0.5 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-084515 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/2 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 55
HOS-084650 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/1 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 100
HOS-084764 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/4 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 144
HOS-084876 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 160 mg/8 mL concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 189
HOS-084986 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Fareston
Fareston 60 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-085621 · Präparat HOS-083163
Theoretically the metabolism of toremifene is inhibited by drugs known to inhibit the CYP3A enzyme
system which is reported to be responsible for its main metabolic pathways. Examples of such drugs
are antifungal imidazoles (ketoconazole); other antifungal agents (itraconazole, voriconazole,
posaconazole); protease inhibitors (ritonavir, nelfinavir), macrolides (clarithromycin, erythromycin,
telithromycine). Concomitant use of those drugs with toremifene should be carefully considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-30T12:24:00Z · SHA-256 3b25a11bbd424fca19782652cfc8662dd4db79f69f35943c40313fed13e66e0e · Passage 685a49cc637468e295a54afd3fa92b51d9800204c6cb80df9af06b295ec124ed · Zeichen 1457–1947 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 17
HOS-086264 · Präparat HOS-083284
Voriconazole
200 q12h 100 q12h ↓ 39% ↓ 24%
Co-administration of voriconazole and ritonavir dosed as a pharmacokinetic
enhancer should be avoided, unless an assessment of the benefit/risk to the patient
justifies the use of voriconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): voriconazole (HOS-084524)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 139c929074788fafdaf415bb86abc70680289a781cde109fb58ed73275cc63b5 · Zeichen 31578–32005 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49
HOS-086448 · Präparat HOS-083284
Voriconazole
200 q12h 100 q12h ↓ 39% ↓ 24%
Co-administration of voriconazole and ritonavir dosed as a pharmacokinetic enhancer
should be avoided, unless an assessment of the benefit/risk to the patient justifies the use
of voriconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): voriconazole (HOS-084524)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage ddaecab5e8e6030df0ef1693a85aa43e90a83bd1d2e9ee6b21ab369529478978 · Zeichen 32635–33076 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090616 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 5e78d73fd3b12aea3ede2eeac1a14a3dfb8e863d7c5ea6929177114d000b7a9c · Zeichen 5491–5914 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090685 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 238f7546225e192c0d4817ab6a1671062b9e93e1fd99e257fa0ce448f21b38a0 · Zeichen 5433–5860 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 17
HOS-108895 · Präparat HOS-093083
Due to induction of lamotrigine In patients starting or stopping
glucuronidation Kaletra while currently taking
maintenance dose of lamotrigine:
Valproate: ↓ lamotrigine dose may need to be
increased if Kaletra is added, or
decreased if Kaletra is
discontinued; therefore plasma
lamotrigine monitoring should be
conducted, particularly before and
during 2 weeks after starting or
stopping Kaletra, in order to see if
lamotrigine dose adjustment is
needed.
In patients currently taking Kaletra
and starting lamotrigine: no dose
adjustments to the recommended
dose escalation of lamotrigine
should be necessary.
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg BID) similar increase in trazodone
Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower
syncope were observed following dose of trazodone should be
co-administration of trazodone considered.
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are
increased due to CYP3A not recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg
BID) as contained in Kaletra
should be avoided unless an
assessment of the benefit/risk to
patient justifies the use of
voriconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage cc67e2cdf7b4bd67992a77fee82c028a01ca61b900711d375f1043368d2697bb · Zeichen 27086–30540 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53
HOS-109012 · Präparat HOS-093083
Due to induction of lamotrigine In patients starting or stopping
glucuronidation Kaletra while currently taking
maintenance dose of lamotrigine:
Valproate: ↓ lamotrigine dose may need to be
increased if Kaletra is added, or
decreased if Kaletra is discontinued;
therefore plasma lamotrigine
monitoring should be conducted,
particularly before and during 2
weeks after starting or stopping
Kaletra, in order to see if lamotrigine
dose adjustment is needed.
In patients currently taking Kaletra
and starting lamotrigine: no dose
adjustments to the recommended
dose escalation of lamotrigine should
be necessary.
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg similar increase in trazodone
BID) Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower dose
syncope were observed following of trazodone should be considered.
co-administration of trazodone
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are not
increased due to CYP3A recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg BID)
as contained in Kaletra should be
avoided unless an assessment of the
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage b7549f913c063162484a547a54d17aa41fc44fb9504b9f1472817c41a1f18572 · Zeichen 26672–29701 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-109013 · Präparat HOS-093083
53
benefit/risk to patient justifies the use
of voriconazole.
Anti-gout agents
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg Cmax: ↑ 1.8-fold with renal and/or hepatic impairment
twice-daily) Due to P-gp and/or CYP3A4 is contraindicated due to a potential
inhibition by ritonavir. increase of colchicine-related serious
and/or life-threatening reactions such
as neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3 and
4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is recommended
in patients with normal renal or
hepatic function if treatment with
Kaletra is required. Refer to
colchicine prescribing information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased risk
of adverse events related to fusidic
acid, notably rhabdomyolysis (see
section 4.3). When used for osteo-
articular infections, where the co-
administration is unavoidable, close
clinical monitoring for muscular
adverse events is strongly
recommended (see section 4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline related
(single dose) AUC: ↑ 22% adverse events, the combination of
Cmax: ↔ bedaquiline and Kaletra should be
(Lopinavir/ritonavir avoided. If the benefit outweighs the
400/100 mg BID, A more pronounced effect on risk, co-administration of bedaquiline
multiple dose) bedaquiline plasma exposures with Kaletra must be done with
may be observed during caution. More frequent
prolonged co-administration with electrocardiogram monitoring and
lopinavir/ritonavir. monitoring of transaminases is
recommended (see section 4.4 and
CYP3A4 inhibition likely due to refer to the bedaquiline SmPC).
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146) bedaquiline (HOS-086268) voriconazole (HOS-084524) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage cad5366a6fb47c00b40c65b02f661a2f3f24b27d6187e7ce6cfffb83a5f12fd8 · Zeichen 29746–34245 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 89
HOS-109088 · Präparat HOS-093083
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg similar increase in trazodone
BID) Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower
syncope were observed following dose of trazodone should be
co-administration of trazodone considered.
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are not
increased due to CYP3A recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg
BID) as contained in Kaletra should
be avoided unless an assessment of
the benefit/risk to patient justifies
the use of voriconazole.
Anti-gout agents:
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg twice Cmax: ↑ 1.8-fold with renal and/or hepatic
daily) Due to P-gp and/or CYP3A4 impairment is contraindicated due
inhibition by ritonavir. to a potential increase of colchicine-
related serious and/or
life-threatening reactions such as
neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3
and 4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is
recommended in patients with
normal renal or hepatic function if
treatment with Kaletra is required.
Refer to colchicine prescribing
information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 9043d84be2324d7e08bc16eeeba0c8c1136fbb4075d51aeb08ee163e186d9cab · Zeichen 28361–32171 im Abschnitt
Gegenanzeigen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 6
HOS-109436 · Präparat HOS-093201
• Ritonavir:
Coadministration with high-dose ritonavir (400 mg and above twice daily) is contraindicated
(see section 4.5). For information on coadministration with lower doses of ritonavir see section 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage b8e39815dbc73f89d9dbbe350356e3e154efd72b02c8f2aeb97c08bbc6767f88 · Zeichen 1656–1887 im Abschnitt
Gegenanzeigen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.3 · PDF-Seite 37
HOS-109528 · Präparat HOS-093201
• Ritonavir:
Coadministration with high-dose ritonavir (400 mg and above twice daily) is contraindicated (see
section 4.5). For information on coadministration with lower doses of ritonavir see section 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 7ca2701500bb6f78fa58d000a520e39be237b400084c22476521c91b9dd73e93 · Zeichen 1655–1886 im Abschnitt
Gegenanzeigen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.3 · PDF-Seite 70
HOS-109592 · Präparat HOS-093201
• Ritonavir:
Coadministration with high-dose ritonavir (400 mg and above twice daily) is contraindicated (see
section 4.5). For information on coadministration with lower doses of ritonavir see section 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 7ca2701500bb6f78fa58d000a520e39be237b400084c22476521c91b9dd73e93 · Zeichen 1657–1888 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-109458 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
12
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) indinavir (HOS-084518) protease (HOS-085623) glucose (HOS-088412) lead (HOS-085592) glyburide (HOS-109273) fluconazole (HOS-087945) astemizole (HOS-085608) ritonavir (HOS-084521) terfenadine (HOS-085607) phenytoin (HOS-084531) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage c43ce720ce152b6ffc284ecb767edcbe81187c3aba91372adac27d1baca516f9 · Zeichen 11584–14886 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-109462 · Präparat HOS-093201
High dose (400 mg BID) Ritonavir Cmax and AUC ↔ Coadministration of voriconazole
Voriconazole Cmax 66% and high doses of ritonavir
Voriconazole AUC 82% (400 mg and above BID) is
contraindicated (see section
4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 530df5e35557ba5f16fdb48250293a63853bb38d42048248bb0a00c8c9b00533 · Zeichen 14888–15354 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-109463 · Präparat HOS-093201
Low dose (100 mg BID)* Ritonavir Cmax 25% Coadministration of voriconazole
Ritonavir AUC 13% and low-dose ritonavir (100 mg
Voriconazole Cmax 24% BID) should be avoided unless
an assessment of the benefit/risk
Voriconazole AUC 39%
to the patient justifies the use of
voriconazole.
Other HIV Protease Inhibitors Not studied clinically. In vitro Careful monitoring for any
(including but not limited to: studies show that voriconazole may occurrence of drug toxicity
saquinavir, amprenavir and inhibit the metabolism of HIV and/or lack of efficacy, and dose
nelfinavir)* protease inhibitors and the adjustment may be needed.
[CYP3A4 substrates and metabolism of voriconazole may
inhibitors] also be inhibited by HIV protease
inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) protease (HOS-085623) saquinavir (HOS-084522) amprenavir (HOS-086183) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 81b452654b014e91adf502a06508cfe5e46ea829e59260fa77bcc7896d35f33b · Zeichen 15356–16561 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.